Longevitix teams up with Buck Institute chief on AI care

Longevitix has entered a collaboration with Eric Verdin, President and Chief Executive Officer of the Buck Institute for Research on Ageing, centred on preventive and longevity medicine.

Verdin will help shape the start-up's scientific direction and support the development of new approaches to personalised, data-driven care.

Founded in early 2025, Longevitix sells a physician-led artificial intelligence platform for clinicians working in preventive, longevity, functional and integrative medicine. The system combines medical records, laboratory results, imaging, wearable data and lifestyle information to generate clinical insights and suggested care plans.

The collaboration brings together a young healthcare technology company and a researcher known for his work on ageing and age-related disease. Verdin has led research in areas including metabolism, epigenetics and longevity, and heads the Buck Institute, a research organisation focused on ageing.

Clinical focus

The tie-up is intended to connect advances in longevity science with day-to-day medical practice. It reflects a wider push in healthcare to move from treating disease after onset to identifying risks earlier and intervening sooner.

AI tools are increasingly being marketed to doctors as a way to process large volumes of patient data and support decision-making. For Longevitix, that means combining structured and unstructured health information from several sources into a single clinical workflow.

Its software is designed to keep physicians in control of care while helping care teams manage ongoing patient engagement between visits. It also offers custom workflows and collaboration tools for clinicians.

Verdin set out his view of the project in a statement.

"I'm pleased to collaborate with the Longevitix team as they work to bridge the gap between advances in longevity research and real-world clinical practice. Longevity science is demonstrating that earlier intervention can have a profound impact on long-term health. There is a tremendous opportunity to use AI to support more proactive, personalized healthcare. Platforms that help clinicians translate complex data into actionable insights will play an important role in bringing those advances into everyday practice," said Eric Verdin, MD, President and Chief Executive Officer of the Buck Institute.

Growing field

Interest in longevity medicine has grown as clinics, technology groups and researchers explore how to apply findings from ageing science beyond the laboratory. Many companies in the sector are trying to turn research on biomarkers, lifestyle interventions and disease risk into clinical products and services for routine care.

The market remains early and fragmented, with approaches ranging from diagnostics and monitoring to personalised prevention plans. A central challenge is showing that large sets of biological and behavioural data can be used in ways that are practical for clinicians and meaningful for patients.

Longevitix positions its software as a tool for physicians rather than a direct-to-consumer health product. It aims to make evidence-based preventive care more accessible by helping doctors interpret complex patient information alongside emerging medical research.

Effie Arditi, the company's Chief Executive Officer, said the partnership reflects an effort to combine scientific research with clinical software.

"Longevity medicine is entering a new era where advances in science and technology can work together to fundamentally change how care is delivered. Dr. Verdin has been at the forefront of understanding the biology of aging and translating research into practical applications that improve a healthy lifespan. By combining that scientific leadership with Longevitix's AI-driven clinical infrastructure, we have an opportunity to make preventive and personalized medicine more accessible to more people," said Arditi.

The company was founded by Arditi, Gaby Hayon and Dr. Neil Panchal. It serves healthcare providers seeking to offer more proactive care based on patient data and longevity research.